23andMe Holding Co.

3.5000+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · MEHCQ · USD

Upcoming Earnings

Report date
≈ -

Key Stats

Market Cap
96.40M
P/E (TTM)
-
Basic EPS (TTM)
-7.76
Dividend Yield
0%

Recent Filings

About

23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. It also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; offers non-controlled medications for treatment of acute and chronic conditions; and provides Ozempic and Wegovy through its weight loss program, offering consumers with access to affordable weight management care. In addition, the company provides research services. 23andMe Holding Co. was founded in 2006 and is headquartered in San Francisco, California.

CEO
Mr. Joseph Anthony Selsavage
IPO
11/23/2020
Employees
257
Sector
Healthcare
Industry
Diagnostics & Research